News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Got the Realtime 8KSpy Alert on AQNM $NRXGQ..... BOOOOM....
z
Nice!! There was a time everyone wrote off KBIO after their bk announcement. All it takes is for someone of 'similar thinking' to come across this one. As I mentioned in a prior post, there's a phase III asset 'on the table' and a very tiny float here. Company already spent hundreds of millions, that another company now doesn't have to spend, developing that asset. Their debt is about 8 mil with a few mil of cash in hand.
Markets can decide if this is worth a ticket to ride! Can be a 'game-changer' if it does 'catch that wind in it's sails'. 
Still here...adding!
I see you out here, all by yourself, behaving 'strangely'!! Are we there yet?
$NRX
Guess you haven't been watching the accumulation here over the past couple days. Also, just and FYI...that was also the plan for KBIO at one point...bk took it to pennies. see where it's trading while in BK?
Sometimes the markets can be a bit 'short sighted'. So here we have a company, unable to pay it's 8mil debt and continue with operations. Wonder what that 'fast track phase III asset' they already spent millions developing might be worth'?
Just sayin'
NRX hold the 0.55$ support line. have add some for next move tomorrow and coming days.
|
Followers
|
9
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
165
|
|
Created
|
12/31/14
|
Type
|
Free
|
| Moderators | |||
RALEIGH, N.C.--(BUSINESS WIRE)--
NephroGenex, Inc. (NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
Pyridorin showed no effect on the QT/QTc interval at the expected therapeutic dose of 300 mg and at a higher dose of 1200 mg. In previous Phase 1 and Phase 2 studies, Pyridorin has shown no effect on the QT/QTc interval in patients with diabetic nephropathy.
“These are important study results that support the use of Pyridorin in patients with diabetic nephropathy, many of whom suffer from cardiovascular disease. They are also important given the concerns over cardiac safety seen with other therapies in development for this disease,” said Chief Executive Officer Pierre Legault. “The overall excellent safety profile we are continuing to see, along with the promising efficacy shown in our Phase 2 trials, continues to suggest that Pyridorin has the potential to broadly address the unmet therapeutic needs of the more than 6 million diabetic patients with kidney disease.”
About Diabetic Nephropathy
Diabetic nephropathy is a chronic, degenerative disease of the kidney caused by diabetes. There are approximately 6 million patients with diabetic nephropathy in the United States (approximately 33% of diagnosed diabetics) and this population is expected to grow. Patients suffering from diabetic nephropathy progress to End Stage Renal Failure (and require dialysis) or death. There are currently no adequate treatments for this disease.
About Pyridorin®
Pyridorin inhibits pathogenic oxidative chemistries, which are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy. Pyridorin inhibits a broad range of these chemistries which we believe accounts for its effectiveness in slowing the progression of nephropathy in diabetic patients as shown in our Phase 2 studies. Our lead drug candidate was also found to be safe and well tolerated in these same studies.
About NephroGenex, Inc.
NephroGenex (NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.
Cautionary Note on Forward-Looking Statements
